Evidence map›Paper›PMID 23463152›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2013

An orexin hotspot in ventral pallidum amplifies hedonic 'liking' for sweetness.

Chao-Yi Ho, Kent C Berridge

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 164 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Hedonic hotspot in rat olfactory tubercle: map for mu-opioid, orexin, and muscimol enhancement of sucrose 'liking'.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  5. Optogenetic Hedonic Hotspots in the Orbitofrontal Cortex and Insula: Causing Enhancement of Sweetness "Liking".The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  6. Ecologically-Valid Emotion Signatures Enhance Mood Disorder Diagnostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Sex Differences in Demand for Highly Palatable Foods: Role of the Orexin System.The international journal of neuropsychopharmacology · 2021
    Article
  18. Article
  19. Pleasure, addiction, and hypocretin (orexin).Handbook of clinical neurology · 2021
    Review
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Chao-Yi HoDepartment of Psychology, University of Michigan, Ann Arbor, MI 48109-1043, USA.
Kent C Berridge
University of Michigan–Ann Arbor · US

Funding

Affective neuroscience of taste reactivityR01MH063649 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BERRIDGE, KENT C. · 2002 to 2024
$7.8M
Cue-triggered Reward SeekingR01DA015188 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BERRIDGE, KENT C. · 2003 to 2021
$4.9M
NIDA NIH HHS DA015188NIDA NIH HHS R01 DA015188NIMH NIH HHS MH63649NIMH NIH HHS R01 MH063649
6 · The paper itself

Abstract

Orexin (hypocretin) is implicated in stimulating appetite as well as arousal, and in both food reward and drug reward. The ventral pallidum (VP) receives orexin projections from lateral hypothalamus neurons (LH), and orexin terminals are especially dense in the posterior half of VP, which is also the location of an opioid hedonic hotspot. The VP hotspot is a roughly cubic-millimeter site where mu opioid stimulation can amplify the hedonic impact of sweetness, expressed as an increase in 'liking' reactions to sucrose taste. The anatomical overlap in posterior VP between opioid hotspot and orexin inputs raises the possibility that the hedonic hotspot might allow orexin to amplify 'liking' too. We examined whether microinjections of orexin-A into the VP hotspot enhance the hedonic impact of sucrose, as assessed via affective taste reactivity measures of 'liking' reactions, and additionally compared effects at nearby sites in adjacent LH and extended amygdala. Taste reactivity results indicated that orexin stimulation specifically in the VP hotspot nearly doubled the magnitude of positive 'liking' reactions elicited by the taste of sucrose. Mapping results for localization of function, aided by Fos plume measures of the local spread of orexin impact, suggested that hedonic enhancement was generated by essentially the same cubic-millimeter of posterior VP previously identified as the opioid hotspot. By contrast, microinjection sites in the anterior half of VP, or in LH or extended amygdala, generally failed to produce any hedonic enhancement. We conclude that an orexin hedonic hotspot exists in posterior VP, with similar boundaries to the opioid hotspot. An orexin hedonic hotspot may permit regulatory hypothalamic circuitry to make foods more 'liked' during hunger by acting through VP. Dysfunction in a VP orexin hotspot in addiction or mood disorders might also contribute to some types of affective psychopathology.

Indexed as

AmygdalaAnimalsBrain MappingGlobus PallidusHypothalamic Area, LateralIntracellular Signaling Peptides and ProteinsMaleMicroinjectionsNeuronsNeuropeptidesOrexinsQuinineRatsSucroseTaste PerceptionIntracellular Signaling Peptides and ProteinsNeuropeptidesOrexinsQuinineSucrose

Identifiers

PMID23463152
PMCPMC3717533
OpenAlexW2163742936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.